Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Q3 2016 Earnings Presentation

26 slides from Sucampo Pharmaceuticals's earnings presentation, Nov 9, 2016

  1. Slide 1: Third Quarter 2016 Corporate Update and Financial Results

    € @ SUCAMPO. Third Quarter 2016 Corporate Update and Financial Results November 9, 2016

  2. Slide 2: Introductions and Forward-Looking Statements

    Introductions and Forward- Looking Statements Silvia Taylor, SVP Investor Relations & Corporate Affairs

  3. Slide 3: Agenda

    Agenda $ sucampo Introductions and Forward-Looking Statements Corporate Update Pipeline Update Financial Update Closing Remarks Silvia Taylor Peter Greenleaf Peter Lichtlen, M._D., Ph.D. Andrew Smith Peter Greenleaf

  4. Slide 4: Forward Looking Statement

    Forward Looking Statement $ sucampo This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. ‘These statements are based on management's current expectations and involve risks and uncertainties, which may cause results t

  5. Slide 5: Q3 2016 - Peter Greenleaf, Chairman and CEO

    Q3 2016 Corporate Update Peter Greenleaf, Chairman and CEO

  6. Slide 6: Continued Financial and Operational Performance

    Continued Financial and Operational Performance $ SUCAMPO * Strong financial performance driven by global performance of AMITIZA — Increased guidance for 2016 — Preliminary 2017 guidance + Resolution of AMITIZA patent litigation with Dr. Reddy's Laboratories + Results from Phase 3 trial of AMITIZA i

  7. Slide 7: Solid Overall Q3 Financial Results

    Solid Overall Q3 Financial Results $ sucampo REVENUE + Overall revenue grew 73% YoY to $57.9M — Increased royalties for AMITIZA in the U.S. — Sales of AMITIZA in Japan — Inclusion of RTU results + Revenue grew 33% when excluding $13.3M RTU-related revenue EARNINGS* Summary of Results Q3-16 % Increas

  8. Slide 8: Strong U.S. AMITIZA Performance

    Strong U.S. AMITIZA Performance + Takeda’s AMITIZA net sales for royalty calculation purposes - Q3 grew 7% YoY to $109M + Royalty revenue grew 7% YoY to $21M —- Driven by price increase in January 2016 and volume + U.S. AMITIZA product sales to Takeda of $10M + Total U.S. revenue of $32M + AMITIZA T

  9. Slide 9: Expected AMITIZA U.S. Growth Drivers

    Expected AMITIZA U.S. Growth Drivers $ sucampo + Key formulary wins (effective 1/1/17): + Added back to CVS Caremark preferred formulary + Elevated to High Performance formulary status for Express Scripts + Additional key formulary wins + Highly-targeted DTC television campaign in select key markets

  10. Slide 10: Japan AMITIZA Performance

    Japan AMITIZA Performance $ sucampo + Sucampo Q3 revenue: $17.4M, growth of 69% YoY + Driven by volume - Increased by more than 40% for first nine months of 2016 + Growth drivers: — Strong market growth — Only branded constipation prescription medicine —- Broad label of constipation

  11. Slide 11: 2016 Guidance Increased

    2016 Guidance Increased $ sucamPo_ + Total revenue: $220 million to $225 million + Adjusted net income: $50 million to $55 million + Adjusted EPS: $1.20 to $1.25 + Adjusted EBITDA: $110 million to $115 million Adjusted net income guidance excludes amortization of acquired intangibles of approximatel

  12. Slide 12: Settlement and License Agreement with Dr. Reddy's

    Settlement and License Agreement with Dr. Reddy’s $ sucamPo_ Resolves litigation in U.S. related to AMITIZA — Provides much greater certainty on future value of AMITIZA franchise — Significantly de-risks AMITIZA businessin later years Dr. Reddy's granted non-exclusive license to market generic in U.

  13. Slide 13: Pipeline Update

    Pipeline Update Peter Lichtlen, M.D., Ph.D., CMO

  14. Slide 14: Pediatric Phase 3 Results with Current Formulation

    Pediatric Phase 3 Results with Current Formulation + Phase 3 trial of AMITIZA vs. placebo in children6 to 17 years of age + Evaluated doses of 12 and 24 mcg over 12 weeks + Primary endpoint of overall spontaneous bowel movement (SBM) response — Never tested in pediatric population with functional co

  15. Slide 15: Pediatric Phase 3 Results with Current Formulation

    Pediatric Phase 3 Results with Current Formulation + Did not achieve primary endpoint of overall SBM response + Did show trend in favor of efficacy + Achieved statistical significance for key secondary endpoints - Overall SBM frequency - Straining — Stool consistency + Well-tolerated + Data warrants

  16. Slide 16: Pediatric Phase 3 Results: Next Steps

    Pediatric Phase 3 Results: Next Steps + Review data with FDA * Continue clinical development of sprinkle formulation for very young patients and adults who may not be willing or able to take the current formulation + Initiate Phase 3 program aimed at adult patients with CIC by the end of this year —

  17. Slide 17: Product Pipeline

    Product Pipeline $ sucampo Development |(s)NDA/ MAA First Indication Sane Approval iMetabol inflamation constipation (6-17 yrs.) ue Ge Pediatric functional constipation ee 2018(1); 2019 (1); 6 mos-5 yrs (1), adult CIC (2) 2017 (2) 2018 (2) Polyamines Familial Adeneomatous Polyposis P3 2018 2019 RTU-

  18. Slide 18: Financial Update

    Financial Update Andrew Smith, CFO

  19. Slide 19: Q3 Revenue

    Q3 Revenue $ sucampo 70.0 60.0 50.0 40.0 $ Million 30.0 20.0 10.0 93.2015 R-Tech Inclusion AMITIZAUS AMITIZA Japan Collaboration 03.2016 Royalty

  20. Slide 20: Q3 Adjusted Net Income

    Q3 Adjusted Net Income $ 25.0 20.0 15.0 $ Million 10.0 5.0 + 00 3.2015 RTU Revenue Margin TaxRate Stock Expense Interest Other 32

  21. Slide 21: Q3 Adjusted EBITDA

    Q3 Adjusted EBITDA $ sucamPo_ 20.0 $ Million 15.0 50 00 3.2015 R-Tech Inclusion _Revenue contribution Other 03 2016

  22. Slide 22: Key Balance Sheet Items

    Key Balance Sheet Items Item | As of 6/30/16 nge As of 12/ Cash, Cash Equivalents and $153.7M ($9.8) $163.5M. Restricted Cash Notes Payable ($218.7M) $33.7M ($252.4M) Net Debt ($65.0M) $23.9M ($88.9M)

  23. Slide 23: 2017 Preliminary Guidance

    2017 Preliminary Guidance $ Total revenue: $220 million to $230 million Adjusted net income: $75 million to $85 million Adjusted EBITDA: $145 million to $155 million Revenue does not include any milestone payments Adjusted net income guidance excludes amortization of acquired intangibles of approxim

  24. Slide 24: Closing Remarks

    Closing Remarks Peter Greenleaf, Chairman and CEO

  25. Slide 25: End of 2016/2017 Areas of Focus

    End of 2016/2017 Areas of Focus $ sucampo 1. Deliver outstanding financial performance, both top and bottom line 2. Interactions with FDA regarding Phase 3 trial results for AMITIZA in the pediatric population and next steps 3. Evaluate and execute on additional opportunities for growth

  26. Slide 26: Q&A Session

    Q&A Session

Sucampo Pharmaceuticals — Q3 2016 Earnings Presentation on 6ix